Morgan Stanley Downgrades Maravai LifeSciences to Equal-Weight, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has downgraded Maravai LifeSciences (NASDAQ:MRVI) from Overweight to Equal-Weight and lowered the price target from $11 to $10.
August 13, 2024 | 9:22 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has downgraded Maravai LifeSciences from Overweight to Equal-Weight and reduced the price target from $11 to $10.
The downgrade from Overweight to Equal-Weight and the reduction in the price target from $11 to $10 by Morgan Stanley is likely to negatively impact the stock price of Maravai LifeSciences in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100